



Elizabeth Xiao-Ru Wang, Ph.D., Principal, Charles River Associates

Dr. Elizabeth Xiao-Ru Wang has extensive experience working on antitrust matters with Chinese regulators. She is highly knowledgeable about cultural and legal system differences across countries and works with clients to navigate challenges associated with merger reviews or investigations. Dr. Wang has submitted reports and presented economic analysis in front of the Chinese agencies, and advised clients on merger reviews, antitrust investigation and private litigation in China. She has published and spoken on various topics related to China's AML enforcement, especially on the competitive and economic analysis frameworks employed in China's merger reviews.

Dr. Wang has provided economic analyses on issues of merger review, intellectual property rights, vertical restraints, exclusionary conducts, price fixing, and assessment of damages, especially in cross-border matters. Dr. Wang has worked with clients in Asia, North America, and Europe. She has been involved in casework in a variety of industries, including health care, high tech industries, financial markets, pharmaceuticals, airlines, and consumer products.

Dr. Wang is an active member of the American Bar Association (ABA). She is a Co-Chair of the China Committee and a Vice Chair of the International Antitrust Committee of the ABA's International Law Section and an active member of the Antitrust Law Section. Dr. Wang won the ABA International Law Section award of 2014 Outstanding Collaboration between Committees.

Dr. Wang has a Ph.D. in economics from the University of Chicago and a B.A. in economics from Peking University in China.